
Señalización PI3K / Akt / mTOR
Los inhibidores de la señalización PI3K/Akt/mTOR son compuestos que se dirigen a las vías de la fosfoinositida 3-cinasa (PI3K), la cinasa Akt y el blanco de la rapamicina en mamíferos (mTOR). Estas vías son reguladores críticos del crecimiento celular, la supervivencia, el metabolismo y la autofagia, lo que las convierte en objetivos clave en la investigación del cáncer y los trastornos metabólicos. Inhibir estas vías puede ayudar a controlar el crecimiento y la proliferación tumoral, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades caracterizadas por una señalización celular desregulada. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de PI3K/Akt/mTOR para apoyar su investigación en oncología, señalización celular y enfermedades metabólicas.
Subcategorías de "Señalización PI3K / Akt / mTOR"
- AMPK(158 productos)
- ATM / ATR(71 productos)
- ADN-PK(51 productos)
- EGFR(572 productos)
- MELK(7 productos)
- PDK(9 productos)
- PI3K(242 productos)
- Quinasa S6(9 productos)
- gsk-3(112 productos)
- mTOR(144 productos)
Mostrar 2 subcategorías más
Se han encontrado 1038 productos de "Señalización PI3K / Akt / mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Fórmula:C20H12BrN5SForma y color:SolidPeso molecular:434.31PI3Kδ-IN-3
CAS:<p>PI3Kδ-IN-3 (TC KHNS 11) is a PI3Kδ inhibitor with an IC50 value of 9 nM.PI3Kδ-IN-3 has a favorable pharmacokinetic profile and inhibits B cell function.</p>Fórmula:C28H24N6O3Pureza:98.43%Forma y color:SolidPeso molecular:492.53EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4OXA-01
CAS:<p>OXA-01 is a potent mTORC1 and mTORC2 inhibitor, with IC 50 values of 29 nM and 7 nM, respectively [1]. OXA-01 demonstrates broad anti-tumor activity.</p>Fórmula:C21H20ClN5O2Forma y color:SolidPeso molecular:409.87BRD1652
CAS:<p>BRD1652 is a highly selective and potent GSK3 inhibitor.</p>Fórmula:C20H20F3N3OPureza:98%Forma y color:SolidPeso molecular:375.39CC260
CAS:<p>CC260 selectively inhibits PI5P4Kα/β (Ki: 40/30 nM), with minimal effect on Plk1/RSK2, useful for metabolic, diabetes, and cancer studies.</p>Fórmula:C24H29Cl2N5O2Forma y color:SolidPeso molecular:490.43AS2541019
CAS:<p>AS2541019 is a selective Phosphatidylinositol-3-kinase p110δ (PI3Kδ) inhibitor.</p>Fórmula:C26H33F2N7O3Forma y color:SolidPeso molecular:529.58CHMFL-PI4K-127
CAS:<p>CHMFL-PI4K-127 (15g) selectively inhibits PfPI4K (IC50=0.9 nM), potent against Plasmodium 3D7 (EC50=25.1 nM), with oral anti-malaria activity.</p>Fórmula:C18H15ClN4O3SForma y color:SolidPeso molecular:402.85EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Fórmula:C17H14N4O4S3Forma y color:SolidPeso molecular:434.51EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Fórmula:C34H43N9O2Forma y color:SolidPeso molecular:609.76EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Forma y color:SolidPeso molecular:480.95JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Fórmula:C31H30ClFN4O3SForma y color:SolidPeso molecular:593.11EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49SIC-19
CAS:<p>SIC-19, a SIK2 inhibitor, functions by promoting the degradation of SIK2 protein via the ubiquitination pathway. It inhibits the growth of cancer cells and sensitizes cells, ovarian cancer organoids, and xenograft models to PARP inhibitors (such as Olaparib).</p>Fórmula:C29H26N4O5S2Forma y color:SolidPeso molecular:574.67EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PForma y color:SolidPeso molecular:759.68PI3Ka-IN-5
CAS:<p>PI3Ka-IN-5 is a potent PI3Kα/mTOR inhibitor, with an IC 50 of 0.7 nM and 3.3 nM, respectively. PI3Ka-IN-5 can be used for the research of colorectal cancer .</p>Fórmula:C30H35N9O5Forma y color:SolidPeso molecular:601.66EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6ON 146040
CAS:<p>ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.</p>Fórmula:C24H23N7O3SPureza:97.39%Forma y color:SolidPeso molecular:489.55P-2281
CAS:<p>P-2281 is an mTOR inhibitor with anticancer and anti-inflammatory properties.P-2281 inhibits dextran sulfate sodium (DSS)-induced colitis by suppressing T-cell</p>Fórmula:C9H8ClN3OPureza:99.95%Forma y color:SolidPeso molecular:209.63
